SPRO - スマ―トプロス (Spero Therapeutics Inc.)

SPROのニュース

   Spero Therapeutics (SPRO) Presents At Ladenburg Thalmann Healthcare Conference - Slideshow  2021/07/16 19:08:59 Seeking Alpha
   Spero Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference  2021/07/07 20:01:00 Intrado Digital Media
CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will give a corporate presentation and be available for virtual one-on-one meetings at the Ladenburg Thalmann Healthcare Conference, taking place virtually from July 13 14, 2021. Details for the presentation are as follows:
   Pfizer, Spero Sign Licensing Deal for SPR206 in Ex-Asia, Ex-U.S. Regions; Street Says Hold  2021/07/06 17:00:10 Smarter Analyst
Global pharmaceutical and biotechnology firm Pfizer (PFE) and biopharmaceutical firm Spero Therapeutics (SPRO) have signed a regional licensing agreement for the latters polymyxin The post Pfizer, Spero Sign Licensing Deal for SPR206 in Ex-Asia, Ex-U.S. Regions; Street Says Hold appeared first on Smarter Analyst .
   Spero Therapeutics Shares Rise 15% After $40 Million Investment From Pfizer - Morningstar  2021/07/06 05:41:30 Morningstar
Spero Therapeutics Shares Rise 15% After $40 Million Investment From Pfizer Morningstar.com
   Everest Medicines: Spero Therapeutics, Pfizer In Deal For SPR206 In Ex-U.S. And Ex-Asia Territories  2021/07/05 10:44:47 Business Insider Markets
(RTTNews) - China''s Everest Medicines announced Monday that its licensing partner Spero Therapeutics, Inc. (SPRO) entered into a regional licensing agreement with Pfizer Inc. (PFE) for SPR206 in territories excluding U.S. and Asia. SPR206 is Spero''s intravenously or IV-administered next-generation polymyxin product candidate being developed to
   Spero Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference  2021/07/07 20:01:00 Intrado Digital Media
CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will give a corporate presentation and be available for virtual one-on-one meetings at the Ladenburg Thalmann Healthcare Conference, taking place virtually from July 13 14, 2021. Details for the presentation are as follows:
   Pfizer, Spero Sign Licensing Deal for SPR206 in Ex-Asia, Ex-U.S. Regions; Street Says Hold  2021/07/06 17:00:10 Smarter Analyst
Global pharmaceutical and biotechnology firm Pfizer (PFE) and biopharmaceutical firm Spero Therapeutics (SPRO) have signed a regional licensing agreement for the latters polymyxin The post Pfizer, Spero Sign Licensing Deal for SPR206 in Ex-Asia, Ex-U.S. Regions; Street Says Hold appeared first on Smarter Analyst .
   Spero Therapeutics Shares Rise 15% After $40 Million Investment From Pfizer - Morningstar  2021/07/06 05:41:30 Morningstar
Spero Therapeutics Shares Rise 15% After $40 Million Investment From Pfizer Morningstar.com
   Everest Medicines: Spero Therapeutics, Pfizer In Deal For SPR206 In Ex-U.S. And Ex-Asia Territories  2021/07/05 10:44:47 Business Insider Markets
(RTTNews) - China''s Everest Medicines announced Monday that its licensing partner Spero Therapeutics, Inc. (SPRO) entered into a regional licensing agreement with Pfizer Inc. (PFE) for SPR206 in territories excluding U.S. and Asia. SPR206 is Spero''s intravenously or IV-administered next-generation polymyxin product candidate being developed to
   Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia Territories  2021/07/05 10:04:00 Business Insider Markets
SHANGHAI, July 5, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative
   Spero Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference  2021/07/07 20:01:00 Intrado Digital Media
CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will give a corporate presentation and be available for virtual one-on-one meetings at the Ladenburg Thalmann Healthcare Conference, taking place virtually from July 13 14, 2021. Details for the presentation are as follows:
   Pfizer, Spero Sign Licensing Deal for SPR206 in Ex-Asia, Ex-U.S. Regions; Street Says Hold  2021/07/06 17:00:10 Smarter Analyst
Global pharmaceutical and biotechnology firm Pfizer (PFE) and biopharmaceutical firm Spero Therapeutics (SPRO) have signed a regional licensing agreement for the latters polymyxin The post Pfizer, Spero Sign Licensing Deal for SPR206 in Ex-Asia, Ex-U.S. Regions; Street Says Hold appeared first on Smarter Analyst .
   Spero Therapeutics Shares Rise 15% After $40 Million Investment From Pfizer - Morningstar  2021/07/06 05:41:30 Morningstar
Spero Therapeutics Shares Rise 15% After $40 Million Investment From Pfizer Morningstar.com
   Everest Medicines: Spero Therapeutics, Pfizer In Deal For SPR206 In Ex-U.S. And Ex-Asia Territories  2021/07/05 10:44:47 Business Insider Markets
(RTTNews) - China''s Everest Medicines announced Monday that its licensing partner Spero Therapeutics, Inc. (SPRO) entered into a regional licensing agreement with Pfizer Inc. (PFE) for SPR206 in territories excluding U.S. and Asia. SPR206 is Spero''s intravenously or IV-administered next-generation polymyxin product candidate being developed to
   Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia Territories  2021/07/05 10:04:00 Business Insider Markets
SHANGHAI, July 5, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative

calendar